开发针对糖尿病视网膜病变的向药物,使用门德尔的随机化药物基因组学
Guodan Liu1, Miao Tian1, Xinge Li1
1Department of Ophthalmology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Frontiers in endocrinology
|October 13, 2025
概括
诺金 (NOG) 蛋白可能会降低通过遗传分析发现的糖尿病视网膜病变风险. 现有的药物如孕激素和雌激醇显示出治疗这种眼睛疾病的潜力.
科学领域:
- 遗传学 遗传学 是一个
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病视网膜病变 (DR) 是导致失明的主要原因.
- 确定DR的新型治疗点对于药物开发至关重要.
研究的目的:
- 使用遗传仪器变量系统地选和验证具有与DR因果关系的可药性蛋白质.
- 基于遗传证据,探索DR治疗的潜在药物标.
主要方法:
- 使用蛋白质定量特征位置 (pQTL) 数据进行双样本门德尔随机化 (MR) 分析.
- 全基因组关联研究 (GWAS) 对DR和可药物化基因编码蛋白的总结数据.
- 灵敏度分析包括异质性,性和同居化测试.
- 蛋白与蛋白相互作用 (PPI) 网络和药物数据库挖掘.
主要成果:
- 诺金 (NOG) 蛋白与DR风险有显著的负因果关系.
- 敏感性分析证实了NOG-DR协会的稳定性和可靠性.
- NOG与BMP信号通路蛋白相互作用;孕激素和雌激素被确定为潜在的治疗化合物.
结论:
- NOG蛋白是一种新的潜在的防护药物对抗DR的标,可能通过BMP信号通路.
- 孕激素和雌激醇被认为是DR的潜在疗法,需要进一步研究.
相关概念视频
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...


